세계의 메티실린 내성 황색포도구균(MRSA) 치료제 시장 - 산업 규모, 점유율, 동향, 기회, 예측 :약품 클래스별, 투여 경로별, 유통 채널별, 지역별, 경쟁(2019-2029년)

Global Methicillin-resistant Staphylococcus Aureus Drugs Market was valued at USD 2.37 billion in 2023 and is anticipated to project steady growth in the forecast period with a CAGR of 5.67% through 2029. The Global Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market is witnessing significant growth as a response to the persistent challenges posed by antibiotic-resistant strains of Staphylococcus aureus. MRSA, a bacterium resistant to traditional antibiotics like methicillin, poses a serious threat, especially in healthcare settings. The market addresses the urgent need for effective drugs to combat MRSA infections, which can range from skin and soft tissue infections to more severe and life-threatening conditions like pneumonia and bloodstream infections. Key drivers of this market include the increasing incidence of MRSA infections worldwide, driven by factors such as prolonged hospital stays, invasive medical procedures, and a growing elderly population. The emergence of community-associated MRSA infections adds to the complexity, necessitating a robust pipeline of drugs for comprehensive treatment. Pharmaceutical companies are actively engaged in research and development to introduce innovative MRSA drugs. This involves exploring new antibiotic classes, combination therapies, and alternative treatment approaches. The focus extends beyond traditional antibiotics to include novel compounds and strategies that counteract MRSA's resistance mechanisms. Geographically, the market reflects a global effort to address MRSA infections. Developed regions with advanced healthcare infrastructures are at the forefront of research and drug development. However, the market also recognizes the increasing prevalence of MRSA in emerging economies, prompting efforts to improve accessibility to effective drugs and healthcare resources. The competitive landscape of the MRSA drugs market is characterized by collaborations, partnerships, and strategic alliances between pharmaceutical companies and research institutions. These initiatives aim to pool expertise, accelerate drug development timelines, and enhance the overall effectiveness of MRSA treatments. In conclusion, the Global MRSA Drugs Market is vital in the ongoing battle against antibiotic-resistant infections. With an increasing focus on innovative drug development, global collaborations, and addressing the evolving challenges posed by MRSA, the market plays a crucial role in advancing healthcare solutions to counteract this formidable pathogen.

Key Market Drivers

Rising Incidence of MRSA Infections

The rising incidence of Methicillin-resistant Staphylococcus Aureus (MRSA) infections stands as a compelling driver in shaping the dynamics of the Global MRSA Drugs Market. MRSA, notorious for its resistance to conventional antibiotics, has witnessed an alarming increase in prevalence globally. This surge is fueled by various factors, including prolonged hospital stays, invasive medical procedures, and the evolving nature of bacterial resistance. In healthcare settings, where MRSA infections are frequently encountered, the prolonged use of antibiotics has contributed to the development of resistant strains. Patients with compromised immune systems or those undergoing surgical interventions are particularly vulnerable, leading to an elevated incidence of MRSA-related complications. Community-associated MRSA infections further contribute to the growing incidence, affecting individuals outside healthcare facilities. Crowded environments, close contact, and shared personal items create conducive conditions for MRSA transmission in communities, adding complexity to the overall landscape. The rise in MRSA infections reflects the adaptability of these bacteria and their ability to thrive in diverse settings. This, in turn, underscores the urgent need for effective drugs capable of addressing the evolving and widespread nature of MRSA. Pharmaceutical companies are responding to this challenge through intensified research and development efforts, focusing on innovative drug formulations and alternative treatment strategies. The market's responsiveness to the escalating incidence of MRSA infections emphasizes the critical role it plays in providing therapeutic solutions to counteract this resilient pathogen and mitigate the impact of antibiotic resistance on global healthcare.

Increased Healthcare-Associated Infections

The Global Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market is significantly influenced by the increased prevalence of healthcare-associated infections (HAIs), a substantial driver shaping market dynamics. MRSA, known for its resistance to conventional antibiotics, poses a heightened risk within healthcare settings, leading to a surge in HAIs. Prolonged hospital stays, invasive medical procedures, and the close proximity of patients in healthcare environments contribute to the elevated transmission of MRSA. Healthcare-associated MRSA infections often occur in patients with compromised immune systems, those undergoing surgical interventions, or individuals with chronic health conditions. The consequences of these infections can range from skin and soft tissue infections to more severe, systemic conditions, increasing the demand for effective MRSA drugs. The intensified focus on healthcare-associated MRSA infections is rooted in the potential for these infections to lead to prolonged hospitalizations, increased healthcare costs, and elevated morbidity and mortality rates. Addressing the challenges posed by MRSA within healthcare facilities requires a robust arsenal of drugs capable of combating this antibiotic-resistant pathogen. Pharmaceutical companies operating in the MRSA Drugs Market recognize the critical importance of developing medications that effectively target healthcare-associated MRSA. Research and development efforts are geared towards innovative formulations, combination therapies, and alternative approaches to address the specific needs of patients within healthcare settings. The market's responsiveness to the increased occurrence of healthcare-associated MRSA infections underscores its pivotal role in providing solutions to mitigate the impact of these infections on global healthcare systems.

Research and Development Initiatives

Research and Development (R&D) initiatives stand at the forefront of efforts within the Global Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market, reflecting a determined response to the challenges posed by antibiotic-resistant strains of Staphylococcus aureus. The urgency to develop effective treatments against MRSA has spurred a wave of innovative exploration and scientific inquiry. Pharmaceutical companies are actively engaged in R&D endeavors, focusing on discovering new antibiotic classes, alternative treatment strategies, and combination therapies to combat MRSA. The adaptable nature of MRSA demands a multifaceted approach that goes beyond traditional antibiotics. One aspect of R&D involves the identification of novel drug targets through advanced genomics and molecular studies. Researchers seek to understand the underlying mechanisms of MRSA resistance, enabling the design of drugs that can circumvent or counteract these mechanisms. Combination therapies, involving the use of multiple drugs with complementary mechanisms of action, are being explored to enhance treatment efficacy and minimize the risk of resistance development. This approach aims to provide a more comprehensive and sustained response against MRSA infections. The alternative treatment strategies, such as bacteriophage therapy or immunotherapies, are under investigation as potential avenues to combat MRSA. These approaches leverage biological agents or the host's immune system to target and neutralize the bacterium. Collaborations between pharmaceutical companies, academic institutions, and research organizations play a pivotal role in advancing MRSA drug development. These collaborations harness diverse expertise, resources, and perspectives, expediting the translation of research findings into viable drug candidates. In conclusion, the Research and Development initiatives in the Global MRSA Drugs Market underscore the industry's commitment to innovation and the imperative of staying ahead of antibiotic resistance. This concerted effort aims to provide effective therapeutic options against MRSA, addressing a critical healthcare challenge and contributing to global efforts in combating antibiotic-resistant infections.

Key Market Challenges

Antibiotic Resistance Dynamics

Antibiotic resistance dynamics constitute a formidable challenge in the Global Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market. MRSA, characterized by its resistance to multiple antibiotics, displays a remarkable ability to adapt and evolve, necessitating constant vigilance in drug development. The dynamic nature of antibiotic resistance in MRSA arises from selective pressures exerted by the widespread use of antibiotics. Prolonged and improper antibiotic use in healthcare settings, agriculture, and communities accelerates the evolution of MRSA strains capable of resisting these medications. The bacteria employ various mechanisms, such as genetic mutations and acquisition of resistance genes, to outsmart the action of antibiotics. MRSA's ability to exchange genetic material with other bacteria enhances its resistance profile. Mobile genetic elements, including plasmids and transposons, facilitate the transfer of resistance genes between bacterial strains, contributing to the diversification and dissemination of antibiotic-resistant MRSA. This continuous adaptation poses a significant challenge for drug developers aiming to create effective MRSA treatments. The challenge is not merely to find new antibiotics but also to anticipate and address the evolving resistance mechanisms employed by MRSA. Multidisciplinary research efforts are essential to decipher the genetic basis of MRSA resistance, allowing for the development of drugs that can withstand the bacterium's adaptability. As the antibiotic resistance dynamics of MRSA persist, the Global MRSA Drugs Market faces the critical task of staying ahead of these evolving mechanisms. Innovations in drug development, informed by a deep understanding of MRSA's adaptive strategies, are imperative to combat the formidable challenge of antibiotic resistance in the context of MRSA infections.

Biofilm Formation

Biofilm formation is a critical aspect influencing the Global Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market, presenting a significant challenge in the effective treatment of MRSA infections. MRSA has a remarkable ability to produce biofilms, complex structures composed of bacterial cells encased in a protective matrix. This biofilm formation contributes to the resilience of MRSA, making it particularly challenging to eradicate. Biofilms act as a shield, providing a protective environment for MRSA to evade the effects of antibiotics and the host immune system. Within these biofilms, MRSA cells communicate and cooperate, enhancing their resistance to conventional treatments. This biofilm-mediated resistance is a major hurdle in the development of drugs that can penetrate and disrupt these structures. The Global MRSA Drugs Market is compelled to address the unique challenges posed by biofilm formation. Pharmaceutical companies are intensifying research efforts to discover drugs with the ability to penetrate and disperse biofilms, rendering MRSA susceptible to treatment. This involves exploring innovative formulations and delivery mechanisms that can effectively target biofilm-embedded MRSA. Developing drugs that specifically target biofilm-associated MRSA infections is crucial for comprehensive treatment strategies. Strategies include disrupting biofilm formation, enhancing the penetration of antibiotics into biofilms, and preventing the bacteria from developing resistance within these structures. In conclusion, biofilm formation by MRSA significantly impacts the Global MRSA Drugs Market by necessitating the development of drugs capable of overcoming the protective nature of biofilms. Innovative approaches targeting biofilm-associated infections are vital to improving the efficacy of MRSA treatments and addressing the challenges posed by this resilient bacterium.

Key Market Trends

Genomic Approaches and Precision Medicine

Genomic approaches and precision medicine are emerging as pivotal strategies in the Global Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market, representing a paradigm shift in the way MRSA infections are understood and treated. The use of genomic information is integral to tailoring therapeutic interventions based on the unique genetic characteristics of individual MRSA strains.

Genomic approaches involve the comprehensive analysis of the genetic makeup of MRSA strains, identifying specific genes associated with antibiotic resistance and virulence. This detailed genetic information allows researchers to gain insights into the mechanisms of resistance, facilitating the development of drugs that target these specific genetic vulnerabilities. Precision medicine, in the context of MRSA, focuses on customizing treatments to the genetic profile of the infecting strain. This patient-centered approach recognizes that not all MRSA strains are identical and may exhibit variations in their response to antibiotics. By leveraging genomic data, precision medicine aims to prescribe the most effective and targeted drugs for a particular MRSA infection, optimizing treatment outcomes. In the Global MRSA Drugs Market, the integration of genomic approaches and precision medicine signifies a departure from the one-size-fits-all model of antibiotic treatment. Pharmaceutical companies are investing in research and development efforts to identify biomarkers and genetic indicators that can guide the selection of appropriate drugs, enhancing the efficacy of MRSA treatments while minimizing the risk of resistance development. As technology advances, the incorporation of genomics into routine clinical practice holds the promise of more effective and tailored interventions against MRSA infections, marking a significant trend in the evolution of MRSA drug development.

Patient-Centric Approaches

Patient-centric approaches are gaining prominence in the Global Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market, reflecting a shift towards tailoring treatments to the unique needs and preferences of individuals grappling with MRSA infections. Recognizing the complexity and severity of MRSA, pharmaceutical companies are increasingly adopting strategies that prioritize the well-being and experiences of patients. In the context of MRSA, patient-centric approaches involve the development of drugs with a focus on improving treatment outcomes, minimizing side effects, and enhancing overall patient satisfaction. The design of formulations that facilitate ease of use, reduce the burden of treatment, and ensure patient adherence to prescribed regimens is a key aspect of patient-centricity. Pharmaceutical companies are exploring innovative drug delivery mechanisms, such as long-acting formulations or convenient oral options, to enhance patient convenience and compliance. Simplifying treatment regimens without compromising efficacy is a crucial goal, considering the often prolonged and intensive nature of MRSA therapies. The patient education and engagement initiatives are becoming integral components of MRSA drug development. Ensuring that patients are well-informed about their treatment, including potential side effects and the importance of adherence, empowers them to actively participate in their healthcare journey. The patient-centric focus also extends to the exploration of therapies with improved safety profiles, seeking to minimize adverse effects and enhance the overall quality of life for individuals undergoing MRSA treatment. As the Global MRSA Drugs Market evolves, embracing patient-centric approaches reflects a commitment to not only addressing the medical challenges posed by MRSA but also enhancing the overall experience and outcomes for individuals facing this formidable bacterial infection.

Segmental Insights

Drug Class Insights

Based on Drug Class, lipopeptides segment dominated the Global Methicillin-resistant Staphylococcus Aureus Drugs Market in 2023. This is ascribed due its efficacy against drug-resistant strains. Lipopeptides, such as daptomycin, exhibit potent bactericidal activity against MRSA, providing a valuable treatment option for challenging infections. Their mechanism of action and ability to target resistant strains contribute to their effectiveness. As MRSA infections pose a significant healthcare challenge globally, the demand for robust and versatile solutions has propelled the dominance of lipopeptides. The segment's success reflects the urgency to combat MRSA infections with innovative and effective pharmaceutical interventions, solidifying lipopeptides as a leading choice in the market.

Distribution Channel Insights

Based on distribution channel, hospital pharmacies segment dominated the Global Methicillin-resistant Staphylococcus Aureus Drugs Market in 2023. This is ascribed due to the critical role hospitals play in managing and treating MRSA infections. Hospitals are primary sites for severe infections, and MRSA often requires complex antibiotic therapies. Hospital pharmacies, integrated within healthcare institutions, offer immediate access to a comprehensive range of MRSA drugs. They ensure timely administration, proper dosage, and monitoring, contributing to effective infection control. The hospitals maintain stringent protocols for drug dispensing, aligning with the seriousness of MRSA infections. The dominance of hospital pharmacies highlights their central position in addressing and controlling MRSA outbreaks within healthcare settings.

Regional Insights

North America holds the largest portion of the market, driven by the robust presence of indigenous companies actively involved in the research and development of drugs targeting Methicillin-resistant Staphylococcus aureus (MRSA) infections prevalent in healthcare settings. Notable entities contributing to this dominance in the North American region include Pfizer Inc., GSK plc., Proctor & Gamble, Novartis AG, among others. The concerted efforts of these companies in developing and introducing new MRSA drugs in the U.S. and Canada are expected to significantly boost the regional market. Meanwhile, the Asia-Pacific region is poised for remarkable growth over the forecast period. This growth is underpinned by factors such as increasing awareness, a burgeoning patient population, and the continuous development of advanced pharmaceutical solutions in the region.

Key Market Players

Melinta Therapeutics LLC

Basilea Pharmaceutica Ltd.

Theravance Biopharma

Wockhardt Limited

Paratek Pharmaceuticals, Inc.

Seres Therapeutics Inc.

Merck & Co. Inc.

AbbVie Inc.

Report Scope:

In this report, the Global Methicillin-resistant Staphylococcus Aureus Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Methicillin-resistant Staphylococcus Aureus Drugs Market, By Drug Class:

Oxazolidinones Lipopeptides Cephalosporin Tetracycline Folate Antagonist Other

Methicillin-resistant Staphylococcus Aureus Drugs Market, By Route of Administration:

Oral Administration Parenteral Administration

Methicillin-resistant Staphylococcus Aureus Drugs Market, By Distribution Channel:

Hospital Pharmacies Retail Pharmacies Online Pharmacies

Methicillin-resistant Staphylococcus Aureus Drugs Market, By Region:

North America

United States

Canada

Mexico

Europe

France

United Kingdom

Italy

Germany

Spain

Asia-Pacific

China

India

Japan

Australia

South Korea

South America

Brazil

Argentina

Colombia

Middle East & Africa

South Africa

Saudi Arabia

UAE

Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Methicillin-resistant Staphylococcus Aureus Drugs Market.

Available Customizations:

Global Methicillin-resistant Staphylococcus Aureus Drugs Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug Class (Oxazolidinones, Lipopeptides, Cephalosporin, Tetracycline, Folate Antagonist, Other)
  • 5.2.2. By Route of Administration (Oral Administration and Parenteral Administration)
  • 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)
  • 5.2.4. By Region
  • 5.2.5. By Company (2023)
• 5.3. Market Map
  • 5.3.1. By Drug Class
  • 5.3.2. By Route of Administration
  • 5.3.3. By Distribution Channel
  • 5.3.4. By Region

6. Asia Pacific Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug Class
  • 6.2.2. By Route of Administration
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. Asia Pacific: Country Analysis
  • 6.3.1. China Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug Class
      • 6.3.1.2.2. By Route of Administration
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. India Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug Class
      • 6.3.2.2.2. By Route of Administration
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Australia Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug Class
      • 6.3.3.2.2. By Route of Administration
      • 6.3.3.2.3. By Distribution Channel
  • 6.3.4. Japan Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Drug Class
      • 6.3.4.2.2. By Route of Administration
      • 6.3.4.2.3. By Distribution Channel
  • 6.3.5. South Korea Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Drug Class
      • 6.3.5.2.2. By Route of Administration
      • 6.3.5.2.3. By Distribution Channel

7. Europe Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Class
  • 7.2.2. By Route of Administration
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug Class
      • 7.3.1.2.2. By Route of Administration
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. Germany Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug Class
      • 7.3.2.2.2. By Route of Administration
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. Spain Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug Class
      • 7.3.3.2.2. By Route of Administration
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. Italy Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drug Class
      • 7.3.4.2.2. By Route of Administration
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. United Kingdom Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drug Class
      • 7.3.5.2.2. By Route of Administration
      • 7.3.5.2.3. By Distribution Channel

8. North America Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Class
  • 8.2.2. By Route of Administration
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. North America: Country Analysis
  • 8.3.1. United States Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug Class
      • 8.3.1.2.2. By Route of Administration
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. Mexico Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug Class
      • 8.3.2.2.2. By Route of Administration
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Canada Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug Class
      • 8.3.3.2.2. By Route of Administration
      • 8.3.3.2.3. By Distribution Channel

9. South America Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug Class
  • 9.2.2. By Route of Administration
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Class
      • 9.3.1.2.2. By Route of Administration
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. Argentina Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Class
      • 9.3.2.2.2. By Route of Administration
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. Colombia Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Class
      • 9.3.3.2.2. By Route of Administration
      • 9.3.3.2.3. By Distribution Channel

10. Middle East and Africa Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drug Class
  • 10.2.2. By Route of Administration
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drug Class
      • 10.3.1.2.2. By Route of Administration
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Saudi Arabia Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drug Class
      • 10.3.2.2.2. By Route of Administration
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. UAE Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drug Class
      • 10.3.3.2.2. By Route of Administration
      • 10.3.3.2.3. By Distribution Channel
  • 10.3.4. Egypt Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook
    • 10.3.4.1. Market Size & Forecast
      • 10.3.4.1.1. By Value
    • 10.3.4.2. Market Share & Forecast
      • 10.3.4.2.1. By Drug Class
      • 10.3.4.2.2. By Route of Administration
      • 10.3.4.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Methicillin-resistant Staphylococcus Aureus Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. Competitive Landscape

• 15.1. Melinta Therapeutics LLC
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Financials (If Listed)
  • 15.1.4. Product & Service Offerings
  • 15.1.5. Recent Developments
  • 15.1.6. Key Personnel
  • 15.1.7. SWOT Analysis
• 15.2. Basilea Pharmaceutica Ltd.
• 15.3. Theravance Biopharma
• 15.4. Wockhardt Limited
• 15.5. Paratek Pharmaceuticals, Inc.
• 15.6. Seres Therapeutics Inc.
• 15.7. Merck & Co. Inc.
• 15.8. AbbVie Inc

16. Strategic Recommendations

17. About Us & Disclaimer